Categories Earnings, Health Care

Regeneron Pharmaceuticals (NASDAQ: REGN): Q3 2019 Earnings Snapshot

— Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported its third-quarter 2019 adjusted earnings of $6.67 per share versus $6.36 per share expected.

— Total revenues grew by 23% to $2.05 billion versus $1.99 billion expected. Eylea sales increased by 16% to $1.19 billion.

Regeneron Pharmaceuticals (REGN) Q3 2019 Earnings Review

— Dupixent sales, which soared by 141% to $633 million, drove higher profitability from antibody collaboration with Sanofi.

— Looking ahead into the full year 2019, the company lowered the Sanofi collaboration revenue outlook to the range of $490 million to $510 million from the prior range of $500 million to $530 million.

— Unreimbursed R&D expense, on a reported basis, is now expected to be $2.36 billion to $2.41 billion, and SG&A expense is now predicted to be between $1.73 billion and $1.78 billion for 2019.

— The forecast for capital expenditure is tightened to the range of $390 million to $420 million from the previous range of $380 million to $420 million for the full year.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

TGT Earnings: Key quarterly highlights from Target’s Q1 2024 financial results

Target Corporation (NYSE: TGT) reported its first quarter 2024 earnings results today. Total revenue decreased 3.1% year-over-year to $24.5 billion. Comparable sales declined 3.7%. Net earnings dipped 1% to $942

Important takeaways from AutoZone’s (AZO) Q3 2024 report

Automotive parts retailer AutoZone, Inc. (NYSE: AZO) reported mixed results for the third quarter of 2024, with earnings exceeding the market’s forecast and sales missing. The management is optimistic about

What to look for when Dollar General (DG) reports Q1 2024 earnings results

Shares of Dollar General Corporation (NYSE: DG) rose over 3% on Tuesday. The stock has dropped 31% over the past 12 months. The discount retailer is scheduled to report its first

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top